Compliance 360° Part 8: Patient Influence On US FDA’s Enforcement Strategy

This is Compliance 360°, a podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this eighth installment, former FDA investigations branch director Ricki Chase explains how the role of the patient influences FDA's enforcement strategy and discusses the agency's recent industry guidance on benefit-risk factors.

MT1701_Compliance360

Patients are playing an ever-increasing role in how US FDA approaches its compliance and enforcement priorities, former agency investigations branch director Ricki Chase says.

Indeed, FDA's Center for Devices and Radiological Health "has been increasingly interested in the patient experience and what role that should play in both regulatory and compliance decisions," Chase says...

More from Compliance

More from Policy & Regulation

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.